Cellular expansion

Chronicle

2025: Global Cell Expansion Technologies Market Size for Immunotherapy and Regenerative Medicine Reached $22.14 Billion for the Year

In 2025, expenditures on the global market for cellular expansion technologies for immunotherapy and regenerative medicine amounted to $22.14 billion. More than half of this amount fell on the North American region. The corresponding data is reflected in the Fortune Business Insights study, the results of which were published on December 26, 2025.

Cell expansion refers to the process of culturing and multiplying isolated cells (e.g., stem or immune) to obtain a large number of them for further research, therapeutic use, or transplantation. Growth of the material can occur in bioreactors using specialized culture media that support the growth and viability of the structures.

The authors of the study cite the increase in the prevalence of chronic diseases such as cancer, cardiovascular ailments and genetic abnormalities as the key driver of the industry. In the treatment of malignancies, immunotherapy is increasingly used - this is a modern method that uses the patient's own immune system to fight the tumor, helping it recognize and destroy cancer cells. The process involves modifying a particular person's own T cells in the laboratory, followed by cultivation and introduction back into the body. Increasing the number of such procedures creates the need for reliable and scalable cellular expansion processes.

Another driver is the development of regenerative medicine: the growing interest in stem cells for tissue and organ repair drives research and development of advanced culture techniques. The shift towards personalized medicine further contributes to the growth of the industry.

Technological advances also have a positive impact on the market. We are talking about the development of high-throughput bioreactors, disposable systems, optimized culture media that increase cell viability and proliferation, etc.

At the same time, certain restraining factors stand out. This, in particular, is a lack of qualified specialists and significant costs. The high cost of materials and equipment makes cellular expansion technologies inaccessible to institutions on a budget. In addition, there may be difficulties in certification.

Analysts segment the market into tools/hardware, consumables and software/services. In 2025, the lion's share of revenue was provided by consumables, while equipment accounted for 27.9%. Depending on the field of application, biopharmaceutical production, cell therapy and regenerative medicine, the development and creation of drugs, etc. are distinguished. The first of the listed destinations dominates with 41.9%. From a geographical point of view, North America leads with 51.8%, or $11.47 billion. At the same time, the United States accounted for $10.91 billion. Significant industry players globally are:

• Thermo Fisher Scientific;
• Danaher Corporation;
• Sartorius;
• Merck;
• Lonza Group;
• Corning Incorporated;
• BD;
• Terumo;
• Miltenyi Biotec;
• Eppendorf SE.

In 2026, the volume of the market in question is expected to reach $24.82 billion. Fortune Business Insights analysts forecast a compound percentage CAGR of 10.22% going forward. Thus, by 2034, costs could increase to about $54 billion.^[1]

Notes